Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients

American Journal of Nephrology

Volumn 35, Issue 2, 2012, Pages 198-208

  Duong, Uyen ^a   Kalantar Zadeh, Kamyar ^a,b,c   Molnar, Miklos Z ^a,g   Zaritsky, Joshua J ^b   Teitelbaum, Isaac ^d   Kovesdy, Csaba P ^e,f   Mehrotra, Rajnish ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anemia; Cardiovascular mortality; Erythropoietin stimulating agent therapy; Hemodialysis; Hemoglobin; Mortality; Peritoneal dialysis

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ADULT; ARTICLE; CAUSE OF DEATH; DOSE RESPONSE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

ADULT; AFRICAN AMERICANS; AGED; ANALYSIS OF VARIANCE; FEMALE; HEALTHCARE DISPARITIES; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84856187020     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000335685     Document Type: Article

References (38)

1. Li S, Foley RN, Collins AJ: Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65: 1864-1869. (Pubitemid 38591037)
2. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
3. Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar-Zadeh K: Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol 2011;6:1973-1981.
4. Molnar MZ, Czira M, Ambrus C, Szeifert L, Szentkiralyi A, Beko G, Rosivall L, Remport A, Novak M, Mucsi I: Anemia is associated with mortality in kidney-transplanted patients -A prospective cohort study. Am J Transplant 2007; 7: 818-824. (Pubitemid 46481205)
5. Kalantar-Zadeh K, Aronoff GR: Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009; 20: 479-487.
6. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK: A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010; 77: 239-246.
7. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
8. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)
9. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
10. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798.
11. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA: Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 2007; 297: 1667-1674. (Pubitemid 46631625)
12. Coyne DW: Use of epoetin in chronic renal failure. JAMA 2007; 297: 1713-1716. (Pubitemid 46631631)
13. Kaysen GA, Muller HG, Ding J, Chertow GM: Challenging the validity of the EPO index. Am J Kidney Dis 2006; 47: 166.
14. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876. (Pubitemid 39445919)
15. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155.
16. Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang O, Rothman KJ: Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: Strengths and limitations. Am J Kidney Dis 2009; 54: 554-560.
17. Bradbury BD, Danese MD, Gleeson M, Critchlow CW: Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dl. Clin J Am Soc Nephrol 2009; 4: 630-637.
18. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K: Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736.
19. Strippoli GF: Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: The clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010; 11: 70.
20. Richardson D, Ford D, Gilg J, Williams AJ: UK Renal Registry 11th Annual Report (December 2008). Chapter 9: Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: National and centre-specific analyses. Nephron Clin Pract 2009; 111(suppl 1):c149-c183.
21. Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, Rivera MT, Torrente J, Portoles J, Gomez-Martino JR: Erythropoietin requirements: A comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol 2003; 16: 697-702. (Pubitemid 38714254)
22. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009; 53: 823-834.
23. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773. (Pubitemid 37187377)
24. Wei M, Bargman JM, Oreopoulos DG: Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 2007; 39: 935-940. (Pubitemid 47365410)
25. Finkelstein FO, Juergensen P, Wang S, Santacroce S, Levine M, Kotanko P, Levin NW, Handelman GJ: Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis. Perit Dial Int 2011; 31: 74-79.
26. Axelsson J, Qureshi AR, Heimburger O, Lindholm B, Stenvinkel P, Barany P: Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis 2005; 46: 628-634. (Pubitemid 41383940)
27. Raja R, Bloom E, Johnson R, Goldstein M: Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: Role of iron deficiency. Adv Perit Dial 1994; 10: 135-138.
28. Streja E, Kovesdy CP, Molnar MZ, Norris KC, Greenland S, Nissenson AR, Kopple JD, Kalantar-Zadeh K: Role of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patients. Am J Kidney Dis 2011; 57: 883-893.
29. Molnar MZ, Mehrotra R, Duong U, Bunnapradist S, Lukowsky LR, Krishnan M, Kovesdy CP, Kalantar-Zadeh K: Dialysis modality and outcomes in kidney, transplant recipients. Clin J Am Soc Nephrol 2011, Epub ahead of print.
30. Molnar MZ, Huang E, Hoshino J, Krishnan M, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K: Association of pretransplant glycemic control with posttransplant outcomes in diabetic kidney transplant recipients. Diabetes Care 2011;34:2536-2541.
31. Molnar MZ, Lukowsky LR, Streja E, Dukkipati R, Jing J, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K: Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease. J Hypertens 2010; 28: 2475-2484.
32. Sampaio MS, Molnar MZ, Kovesdy CP, Mehrotra R, Mucsi I, Sim JJ, Krishnan M, Nissenson AR, Kalantar-Zadeh K: Association of pretransplant serum phosphorus with posttransplant outcomes. Clin J Am Soc Nephrol 2011;6:2712-2721.
33. Miller JE, Kovesdy CP, Norris KC, Mehrotra R, Nissenson AR, Kopple JD, Kalantar-Zadeh K: Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol 2010; 32: 403-413.
34. Molnar MZ, Kovesdy CP, Musci I, Bunnapradist S, Streja E, Krishnan M, Kalantar-Zadeh K: Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney Int 2011;80:218-224.
35. Duong U, Mehrotra R, Molnar MZ, Noori N, Kovesdy CP, Nissenson AR, Kalantar-Zadeh K: Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011;6:1041-1048.
36. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE study. Choices for healthy outcomes in caring for ESRD. J Am Soc Nephrol 2000; 11: 520-529. (Pubitemid 30115082)
37. Misra M, Vonesh E, Van Stone JC, Moore HL, Prowant B, Nolph KD: Effect of cause and time of dropout on the residual GFR: A comparative analysis of the decline of GFR on dialysis. Kidney Int 2001; 59: 754-763. (Pubitemid 32157942)
38. Mehrotra R, Duong U, Jiwakanon S, Kovesdy CP, Moran J, Kopple JD, Kalantar-Zadeh K: Serum albumin as a predictor of mortality in peritoneal dialysis: Comparisons with hemodialysis. Am J Kidney Dis 2011; 58: 418-428.